Among the emerging applications of 3D printing in healthcare, regenerative soft tissue reconstruction has seen the least clinical progress and carries some of the highest unmet patient need.
Every year, hundreds of thousands of women undergo lumpectomy, the surgical removal of a cancerous breast tumor, and the majority walk away cancer-free. What many also walk away with permanently is a contour deformity. For most of these patients, there is simply no good reconstructive option available.
GenesisTissue Inc., an early-stage biotechnology research company, is trying to change that. Their lead product, Regenerative Breast Tissue (RBT), is a bioprinted, personalized, biodegradable synthetic scaffold designed to fill a soft tissue void, support a fat graft, and ultimately make way for the body’s own tissue to take over.
I spoke with Katie Weimer, CEO and Co-Founder of GenesisTissue, about what makes their approach different, what remains unsolved, and what she sees as open questions the field has yet to fully reckon with.
Wish to know more medical insights? Register now for our AMA: Healthcare 2026 online conference!
The High Cost of Leaving Defects Uncorrected
Current reconstructive options for lumpectomy patients remain largely inadequate, and Weimer is frank about why. “Surgeons often have no choice but to leave defects uncorrected, resulting in contour deformities, asymmetry, and ultimately a diminished quality of life,” Weimer said.
Standard silicone implants were not designed for the irregular voids left by partial resection, particularly after radiation therapy, which hardens and damages surrounding tissue.
For full-breast reconstruction and cosmetic augmentation, they carry their own well-documented risks, among them infection, capsular contracture, rupture, and malposition. The gap has persisted for decades, and the patients who fall into it have not gone unnoticed. “We regularly get emails from patients asking when our solution will be available,” Weimer said.
The scaffold maintains the shape and volume of the reconstructed area while the fat graft takes hold, and its porous architecture supports fat cell survival and vascular ingrowth, the formation of new blood vessels essential for long-term tissue viability.
It provides structural support for three to six months, enabling fat retention and tissue maturation, and fully biodegrades over six to twelve months, leaving behind only the patient’s regenerated adipose tissue. No permanent foreign body remains.
Weimer is clear about what she sees as RBT’s advantage over prior attempts in the space. “RBT is differentiated by its soft, breast-like feel, personalized and structurally robust scaffold design, compatibility with adjuvant therapies, and scalable manufacturing using medical-grade, light-based 3D printing,” she said.
Personalization is central to that claim. Because lumpectomy defects vary enormously in size, shape, and location, a one-size-fits-all scaffold is unlikely to produce optimal outcomes.
GenesisTissue envisions a workflow in which each patient’s defect is imaged, modeled, and used to generate a custom-printed scaffold matched to that specific void, drawing on the leadership team’s track record commercializing personalized surgical workflows, though Weimer acknowledges the full workflow is still being finalized.
The technical challenge that has demanded the most from the team is degradation timing. Ask Weimer about it and she is precise. “The scaffold needs to remain strong and flexible long enough to physically support and protect the fat graft, while also degrading in sync with fat graft maturation and vascular integration,” she said. “If it degrades too quickly, structural support is lost before the tissue stabilizes; too slowly, and it can interfere with regeneration.”
Getting that timing right is difficult to design for in the laboratory and even harder to verify. Standard in vitro degradation tests do not accurately reflect what happens inside a fat-rich, low-turnover tissue environment, and published data correlating in vitro and in vivo degradation behavior is scarce.
“In vivo studies are very time- and cost-intensive,” Weimer acknowledged, “and iteration is much slower and less accessible.” GenesisTissue reports having identified a finalist biomaterial with in vitro data supporting biocompatibility and degradation behavior, though human-equivalent performance remains to be demonstrated.
The Regulatory Tightrope to Commercial Scale
On the regulatory and commercial side, GenesisTissue expects RBT to be regulated via the US FDA’s Center for Devices and Radiological Health (CDRH), through a Premarket Approval (PMA) pathway, which requires clinical trial data in human subjects, a process the company has not yet entered.
It plans to apply to the FDA’s Safer Technologies Program (STeP) to secure more frequent agency interaction during development. Weimer is relatively straightforward about reimbursement, noting that an initial assessment suggests RBT can align with existing CPT coding and DRG structures for breast reconstruction, which would ease the commercial path considerably for a first-in-class product.
The broader market for next-generation breast implants and regenerative soft tissue is drawing significant attention, and Weimer acknowledges the excitement while pointing to specific areas where she believes the field’s discussions could be more rigorous.
“Developing a novel degradable implantable tissue scaffold is incredibly hard, expensive, and time intensive,” she said. “People will often use terms like bioresorbable and bioabsorbable interchangeably, even though they can mean very different things depending on how the material degrades and clears from the body.”
“Questions around what degradation byproducts are released, how those byproducts accumulate, are used, or are safely cleared, and how local tissue responds over time are all important,” she adds.
She is equally frank about the limits of what has been demonstrated so far, including by her own company. “It is one thing to regenerate a small soft tissue defect,” Weimer said, “but much harder to regenerate larger clinically relevant volumes while maintaining shape and long-term tissue survival.”
GenesisTissue is initially focused on breast reconstruction, but she sees the platform extending to soft tissue loss from trauma, congenital conditions, pressure injuries, and surgical defects if the foundational science bears out.
The graveyard of bioprinting and tissue engineering startups is well-populated with companies that had compelling technology and failed on the translation from lab to patient. Weimer describes GenesisTissue as lean and highly focused, staying close to the science, the engineering, and the clinical problem.
Whether that focus is enough remains an open question. What is not in doubt is the need. Patients are reaching out. Surgeons are improvising.
And for the hundreds of thousands of women who undergo breast-conserving surgery each year, the question of what happens to the shape of their body after the cancer is removed deserves a better answer than the field has managed to provide so far.
3D Printing Industry is inviting speakers for its 2026 Additive Manufacturing Applications (AMA) series, covering Energy, Healthcare, Automotive and Mobility, Aerospace, Space and Defense, and Software. Each online event focuses on real production deployments, qualification, and supply chain integration. Practitioners interested in contributing can complete the call for speakers form here.
To stay up to date with the latest 3D printing news, don’t forget to subscribe to the 3D Printing Industry newsletter or follow us on LinkedIn.
Explore the full Future of 3D Printing and Executive Survey series from 3D Printing Industry, featuring perspectives from CEOs, engineers, and industry leaders on the industrialization of additive manufacturing, 3D printing industry trends 2026, qualification, supply chains, and additive manufacturing industry analysis.
Featured image shows AMA Healthcare 2026. Image by 3D Printing Industry.
